Dr Lal Pathlabs Dividend Record Date on Aug 6: Declared Interim Dividend of ₹6

Dr Lal Pathlabs Ltd has set Aug 6, 2025, as the record date for its interim dividend. On July 31, 2025, Dr Lal Pathlabs board declared an interim dividend of ₹6 per share. 

Dr Lal Pathlabs Ltd said in an exchange filing, “The Board of Directors declared an interim dividend of INR 6/- per equity share (@ 60% on a face value of INR 10/- each) for the financial year 2025-26. The record date for the purpose of payment of the interim dividend shall be August 06, 2025. The Interim Dividend will be dispatched/ credited within 30 days of its declaration” 

What Does Dr Lal Pathlabs Dividend Record Date Mean for Shareholders?

As Dr Lal Pathlabs has set Aug 6 as the record date for its interim dividend, meaning that Aug 5 marks the last day to buy Dr Lal Pathlabs shares to become eligible for the interim dividend. Further, any shares bought on or after Aug 6 (record date) won't be eligible for the interim dividend due to the T+1 settlement rule.

Also Read: Upcoming Dividends in August 2025: Eicher Motors, MCX, and PTC India, Among Others

Dr Lal Pathlabs Q4FY25 Segment Performance 

Dr. Lal PathLabs Limited, a premier diagnostic and healthcare services provider in India, has announced its financial results for the quarter ended June 30, 2025 (Q1 FY26). The Company reported a robust 11.3% year-on-year growth in revenue, reflecting strong operational performance and continued market leadership. EBITDA rose by 13.1%, with a healthy margin of 28.7%, while Profit After Tax (PAT) saw a notable increase of 24.3%, with a margin of 20.0%. In recognition of this strong performance, the Board has declared an interim dividend of ₹6 per share for Q1 FY26.

For investors tracking Dr Lal Pathlabs performance, holding shares through a Demat account ensures secure and seamless access to corporate actions like dividends and earnings updates.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.